When will the patents on BUPIVACAINE HYDROCHLORIDE expire, and when will generic BUPIVACAINE HYDROCHLORIDE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE	bupivacaine hydrochloride; epinephrine	INJECTABLE;INJECTION	071170-001	Jun 16, 1988	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
B Braun Medical	BUPIVACAINE HYDROCHLORIDE	bupivacaine hydrochloride	INJECTABLE;SPINAL	209087-001	Apr 2, 2019	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Eugia Pharma	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE	bupivacaine hydrochloride	INJECTABLE;INJECTION	203895-003	Nov 5, 2013	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	BUPIVACAINE HYDROCHLORIDE KIT	bupivacaine hydrochloride	INJECTABLE;INJECTION	019978-002	Sep 3, 1992		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 6, 2026

Bupivacaine Hydrochloride Investment Scenario and Fundamentals Analysis (IP, Exclusivity, Generics Risk, and Commercial Outlook)

Executive summary: Bupivacaine hydrochloride is an established local anesthetic with a mature generic market, limited branded cash flow, and low near-term IP upside versus newer anesthesia platforms. Investment returns typically depend on (1) channel position (hospital contracting and formulary placement), (2) differentiation through delivery systems or concentration/volume SKUs, and (3) avoiding product-level regulatory and patent bottlenecks tied to specific presentations (injectable solutions, epidural products, and extended-release variants when present). Patent risk is concentrated in presentation-specific formulations, manufacturing methods, and method-of-use claims rather than the core active ingredient.

Implication for investors and acquirers: For bupivacaine hydrochloride, the “fundamentals” lens is less about new molecular exclusivity and more about portfolio defensibility at the NDC and shelf level, including Orange Book patent coverage, any remaining method-of-use or formulation protection, and the litigation posture around specific generics. Most upside comes from operational execution (supply reliability, pricing, contracting) and from targeted differentiation by SKU.

What is bupivacaine hydrochloride and where does it fit commercially?

Core profile. Bupivacaine hydrochloride is an amide local anesthetic used for regional anesthesia (peripheral nerve blocks, epidural anesthesia, and local infiltration). In hospital settings, it is typically stocked through standard formulary channels and purchased under group purchasing organization (GPO) and payer-aligned contracting.

Commercial determinants that matter for investment:

Hospital utilization: elective vs acute procedure volumes (orthopedics, obstetrics, pain management).
Mix across settings: OR anesthesia versus procedural pain clinics.
SKU granularity: concentration (mg/mL), total volume per vial, and route (local infiltration versus epidural).
Concentration-driven contracting: facilities may prefer standardized concentrations to reduce dosing errors.
Supply continuity: shortages or manufacturing disruptions can temporarily improve pricing power for compliant suppliers.

Investor-relevant metric set (what moves gross margin and revenue share):

Net pricing vs tender benchmarks by concentration/volume
Share of hospital accounts using preferred NDCs
Trend in utilization under bundled payment pressure
Turnover and inventory holding costs driven by procurement cycles

What patents protect bupivacaine hydrochloride in the US and how many are still active?

High-level reality for the drug substance. For most long-established small-molecule injectables, active-ingredient patents have largely expired, shifting protection to:

Formulations (stabilizers, pH, buffering systems, and excipient selection)
Concentration/volume presentations tied to specific NDCs
Manufacturing processes (sterilization, filtration, impurity control)
Method-of-use (specific administration regimens, block techniques, or clinical protocols)
Combination products (if any presentation combines active ingredients)

Featured snippet answer: Patent protection for bupivacaine hydrochloride in the US is typically presentation-specific, with the meaningful coverage concentrated in Orange Book-listed patents for particular NDCs, not in the underlying drug substance.

How patent estates usually map to product risk

Drug-substance patents: generally expired for bupivacaine.
Oral or non-injectable patents: typically irrelevant because bupivacaine is primarily an injectable/local anesthetic.
Presentation patents: most commonly still relevant, especially for specific concentration or volume vials/syringes.
Extended-release variants: if offered in-market under separate product lines, they carry distinct IP that can be materially different from standard immediate-release bupivacaine.

Investment lens: When evaluating any prospective acquisition or licensing, diligence should focus on Orange Book patent coverage for the exact NDCs in the target revenue stream, then map that coverage to expected generic entry pathways.

What is the Orange Book status of bupivacaine hydrochloride products?

Featured snippet answer: Orange Book status is NDC-specific; bupivacaine hydrochloride products typically show limited or expired exclusivity at the product level for many presentations, with any remaining protection appearing through listed patents tied to specific formulation/manufacturing or presentation.

How Orange Book listings should be used in diligence

Identify the listed patents by NDC for the target product portfolio.
Record the expiration dates and the scope (composition vs method of use vs formulation/manufacturing).
Check for Paragraph IV history indicating generic challenges.
Assess whether the product is “orphaned” by a weak patent stack or “defended” by multiple listed patents with litigation history.

Investment implication: In a mature generic class, buyers often discount revenue if Orange Book lists are thin or consistently bypassed in Paragraph IV filings.

When does bupivacaine hydrochloride lose exclusivity and patent protection?

Featured snippet answer: For bupivacaine, exclusivity typically ended for most core active-ingredient and early formulation patents years ago; any remaining exclusivity is typically tied to specific NDC presentations and the latest-prosecuted formulation/manufacturing or method-of-use patents.

Practical timeline structure for investors

Patent expirations: the controlling dates are NDC-specific.
Exclusivity: for small molecules, market exclusivity is typically less dominant than patents; when present, it is NDC-specific.
Generic launch windows: determined by patent expiry plus any litigation stay/appeal outcomes triggered by ANDA filings.

Investment implication: The relevant question is not “when does bupivacaine lose exclusivity overall,” but “when does the exact target NDC’s last listed patent end,” and whether there is a history of generic carve-outs.

How strong is the patent estate for bupivacaine hydrochloride: formulation vs method-of-use vs manufacturing?

Typical pattern in mature local anesthetics

Formulation patents: strength depends on excipient and pH/buffering strategy, impurity profile control, and stability data.
Method-of-use patents: often weaker when clinical standards evolve, but can still delay a first generic entry if tied to a specific administration approach.
Manufacturing/process patents: can block “skinny” variants if process is hard to replicate, but they may be easier to design around than composition claims.

Featured snippet answer: In bupivacaine, the most investment-relevant IP is usually formulation/presentation-specific and tied to enforceable Orange Book-listed patents for defined NDCs, not broad claims to “bupivacaine use.”

What courts and ANDA challengers typically target

Carve-outs for dosage form and concentration
Differences in excipient system and pH buffering
Demonstrated equivalence arguments for stability and impurity profiles
Process design-around where composition claims are broad or absent

Are there Paragraph IV challenges or ANDA litigation affecting bupivacaine hydrochloride?

Featured snippet answer: Paragraph IV challenges are typically evaluated at the NDC/presentation level, not for “bupivacaine” generically. Material price or supply impact occurs only when challenges align with product expiration and settlement terms that allow timely launch.

What to look for in litigation files (investment-grade checklist)

Which NDCs are asserted
Claim categories asserted (composition vs method-of-use vs process)
Whether a settlement triggers “authorized generic” or delayed launch
Any court findings that narrow claim scope for future filings

Investment implication: In local anesthetic generics, the biggest downside usually comes from a settlement that clears launch dates earlier than investors modeled, or from multiple-to-one consolidation at tendered pricing levels.

How does bupivacaine hydrochloride compare with lidocaine and ropivacaine in patent and market risk?

Market positioning.

Lidocaine: broader and often more entrenched across local infiltration; extensive generic competition.
Ropivacaine: can have distinct market perception, and depending on presentation, may have a different patent landscape.
Bupivacaine: mature generic availability, with differentiation more likely at formulation/presentation level.

Investment comparison framework

Patent stack durability: bupivacaine usually has less defensible active-ingredient IP than newer entries.
Tender economics: across all three, contracting dominates; brand differentiation matters only where clinicians perceive safety or efficacy differences and procurement allows.
SKU strategy: the most defensible plays are concentration and device formats tied to user workflows.

Featured snippet answer: Bupivacaine generally profiles as “high generic exposure, low molecule-level IP,” so investors should expect economics to hinge on presentation-level defenses and operational execution rather than long-duration exclusivity.

What generic entry risks exist for bupivacaine hydrochloride?

Featured snippet answer: Generic entry risk is determined by (1) whether Orange Book-listed patents for the specific NDCs remain active, (2) whether multiple ANDA filers are waiting to launch, and (3) whether settlements or court rulings accelerate entry.

Where generic launches usually compress revenue

Concentration/volume SKUs used at scale in hospital settings
Vial sizes that are standardized across formularies
Products with stable procurement and predictable tender schedules

How to translate launch risk into financial exposure

Model price erosion after launch based on historical tender declines for comparable local anesthetic SKUs.
Assume switching costs are modest unless the incumbent product is embedded in a standardized protocol.
Track inventory and supply planning around expiry and known launch windows.

What formulations are protected by bupivacaine hydrochloride patents?

Featured snippet answer: Protection is often concentrated in the injectable solution’s presentation details: concentration, volume, excipient system, and pH control, plus sterilization/manufacturing processes that affect impurities and stability.

Common formulation levers in injectable local anesthetics

Buffer system and pH target for stability
Sodium chloride or other tonicity adjusters
Preservatives (where applicable) and compatibility with containers
Sterilization method controls and impurity profile requirements

Investment implication: A competitor can sometimes enter by launching a different concentration/volume or by using a non-infringing formulation, depending on claim scope. That makes NDC-level product mapping critical.

What manufacturing and supply/IP barriers can protect incumbents?

Featured snippet answer: In mature small-molecule injectables, manufacturing quality and validated processes can create practical barriers even after formal IP expires, but they rarely prevent generic entry indefinitely.

Barriers that can still matter

Batch release specifications linked to impurities and water content
Container closure system compatibility validation
Sterility assurance controls and validated filtration steps
Scale-up capacity under GMP timelines

Investment implication: If the incumbent has superior supply reliability or lower defect rates, it can retain share even with generic competition, translating into better realized margins.

How do distribution contracts and hospital formulary dynamics affect returns for bupivacaine?

Featured snippet answer: Hospital procurement cycles and tender-based pricing dominate returns in bupivacaine, so investment upside comes from account penetration and contract renewal discipline rather than scientific differentiation.

Commercial mechanics that drive revenue stability

Multi-year GPO contracts and their renegotiation cadence
Clause structure around shortages and substitute products
Formulary tiering: restricted vs unrestricted status
Training and protocol adherence for regional anesthesia services

Investment implication: A product’s IP may be less relevant than its contracting strategy once generics are present.

What biosimilar risk exists for bupivacaine hydrochloride?

Featured snippet answer: None. Bupivacaine hydrochloride is a small-molecule drug, not a biologic, so biosimilar pathways do not apply.

Key commercialization scenarios for investors (base, downside, upside)

Base case (most probable for mature class)

Ongoing generic pressure at the NDC level
Incumbent maintains share through contracting and reliability
Revenue growth is minimal; margin improves only via supply and cost efficiencies

Downside case

Accelerated entry on high-volume NDCs after expiration or adverse litigation outcomes
Tender price reset compresses realized pricing
Loss of formulary positioning triggers irreversible switching and volume drop

Upside case

Incumbent holds a stronger than expected patent stack on select NDCs through late-expiring formulation/manufacturing or method-of-use coverage
Or successful launch of differentiated presentation sustains tender competitiveness
Contract wins in high-volume systems offset price compression

Investment implication: For bupivacaine, the upside tends to be narrow and presentation-specific, so deal underwriting should be granular at NDC and contract level.

Due diligence checklist for a bupivacaine hydrochloride investment or licensing deal

NDC-level Orange Book mapping: last listed patent by NDC, patent type, and expiration schedule.
Litigation and Paragraph IV history: challenged NDCs and whether settlement accelerates generic entry.
Portfolio concentration: revenue share by NDC, concentration, and volume.
Contract exposure: major customers under tender schedules, renewal dates, and substitute clauses.
Supply chain robustness: redundant manufacturing sites and batch release performance.
Regulatory readiness: ability to support FDA inspections, post-approval changes, and labeling updates.
Design-around risk: whether competitors can enter with alternate excipients/pH or different presentation while avoiding infringement.

Key Takeaways

Bupivacaine hydrochloride is a mature local anesthetic where investment returns depend on presentation-level defensibility (Orange Book/NDC-specific patents) and hospital contracting execution, not molecule-level IP.
Generic entry risk is concentrated in the NDCs that drive revenue; underwriting should model price erosion after launch based on tender dynamics.
Patent strength is usually limited to formulation, manufacturing, and method-of-use claims for specific presentations; broad active-ingredient exclusivity is largely exhausted.
Biosimilar risk is not applicable.
The most investable opportunities are differentiated SKUs or portfolios with durable NDC-specific patent and/or strong supply reliability advantages.

FAQs

1) What NDCs matter most for bupivacaine hydrochloride revenue risk?
Those tied to high-volume hospital use and standardized concentrations/volumes under major contract tenders; assess them against the latest Orange Book listed patents.

2) What patent types most often delay generic bupivacaine entry?
Presentation-specific formulation, manufacturing/process, and narrow method-of-use claims listed in the Orange Book for the exact NDC being launched.

3) How do settlement agreements typically impact launch timing for bupivacaine generics?
They can set earlier or later effective launch dates and may include authorized generic provisions; launch risk should be modeled from NDC-specific settlement terms.

4) Does bupivacaine have clinically meaningful competition advantages over lidocaine or ropivacaine?
Market share is typically determined by protocol fit and contracting; clinician preference can matter, but pricing and availability usually dominate.

5) What operational factors can offset generic pricing pressure for bupivacaine?
Consistent supply reliability, low defect rates, fast fill performance, and successful contracting that preserves formulary placement.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Drug Approval Reports and related information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases-drug-innovation
FDA. (n.d.). ANDA information and regulatory pathways. U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

US Patents:	0
Applicants:	13
NDAs:	35

BUPIVACAINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Bupivacaine Hydrochloride, and when can generic versions of Bupivacaine Hydrochloride launch?

AI Deep Research

Questions you can ask:

Summary for BUPIVACAINE HYDROCHLORIDE

US Patents and Regulatory Information for BUPIVACAINE HYDROCHLORIDE